Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents

A compound of Formula I:

• or a pharmaceutically acceptable salt, wherein:
• A is a cycloalkyl or heterocycloalkyl, optionally substituted by one or more R6 groups such that m is an integer from 0 to 5 inclusive, and wherein said heterocycloalkyl has 1-2 heteroatoms selected from N, O and S;
• and
• wherein R and R6 are each independently selected from the group consisting of H, alkyl, alkyl-R7, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, CH2-heteroaryl, aralkyl, halogen, NO2, CN, CF3, OH, O-alkyl, O-alkyl-R7, O-cycloalkyl, O-heterocycloalkyl, O-aryl, O-heteroaryl, NH2, NH-alkyl, NH-alkyl-R7, NH-cycloalkyl, NH-heterocycloalkyl, NH-aryl, NH-heteroaryl, NH—R7, NHO-aryl, NHCH2-aryl, N-(alkyl)2, N-(cycloalkyl)2, N-(heterocycloalkyl)2, N-(aryl)2, N-(heteroaryl)2, N-(alkyl)(R7), N-(cycloalkyl)(R7), N-(heterocycloalkyl)(R7), N-(aryl)(R7), N-(heteroaryl)(R7), COOH, CONH2, CONH-alkyl, CONH-aryl, CON-(alkyl)(R7), CON(aryl)(R7), CON(heteroaryl)(R7), CONH—R7, SO3H, SO2-alkyl, SO2-alkyl-R7, SO2-aryl, SO2-aryl-R7, SO2NH2, SO2NH-R7, CO-alkyl, CO-alkyl-R7, CO-aryl, CO-aryl-R7, CO—R7, and COOR7;
• R1, R2, R3, and R4 are each independently selected from the group consisting of H, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, CH2-heteroaryl, aralkyl, O-cycloalkyl, O-heterocycloalkyl, O-aryl, O-heteroaryl, NH-cycloalkyl, NH-heterocycloalkyl, NH-aryl, NH-heteroaryl, NHO-aryl, NHCH2-aryl, N-(cycloalkyl)2, N-(heterocycloalkyl)2, N-(aryl)2, N-(heteroaryl)2, N-(cycloalkyl)(R7), N-(heterocycloalkyl)(R7), N-(aryl)(R7), N-(heteroaryl)(R7), S-(heteroaryl)(R7), CONH-aryl, CON(aryl)(R7), CON(heteroaryl)(R7), SO2-aryl, SO2-aryl-R7, CO-aryl, and CO-aryl-R7, with the proviso that at least one of R1, R2, R3 and R4 is not H;
• and
• wherein R7 is selected from the group consisting of H, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, halogen, NO2, CN, CF3, OH, O-alkyl, O-cycloalkyl, O-heterocycloalkyl, O-aryl, O-heteroaryl, NH2, NH-alkyl, NH-cycloalkyl, NH-heterocycloalkyl, NH-aryl, NH-heteroaryl, NH—R10, N-(alkyl)2, N-(cycloalkyl)2, N-(heterocycloalkyl)2, N-(aryl)2, N-(heteroaryl)2, COOH, COO-alkyl, CONH2, CONH-alkyl, CONH-aryl, SO3H, SO2-alkyl, SO2-aryl, SO2NH2, CO-alkyl, CO-aryl;
• R5 is selected from alkyl, O-alkyl, CN, and halogen;
• and
• wherein said heterocycloalkyl and heteroaryl groups comprise 1-2 heteroatoms selected from N, S and O, and wherein said alkyl, cycloalkyl, heterocycloalkyl, aralkyl, aryl and heteroaryl groups may be optionally substituted with one or more groups selected from halogen, alkyl, CN, OH, O-methyl, O-ethyl, O-CF3, NH2, COOH, CONH2, heterocycloalkyl, CO-heterocycloalkyl, CF3, and SO2N(CH3)2.